Tuesday 14
Evolution of pathogens
Chaired by: Daniel Kahn
› 15:05 - 15:25 (20min)
Lentiviral large-scale sequence optimization: another way towards an HIV vaccine?
Nicolas Vabret  1  , Marc Bailly-Bechet  2, *@  , Alice Lepelley  3  , Bernard Verrier  4  , Frédéric Tangy  5  
1 : Icahn School of Medecine, Mount Sinai Hospital
Icahn Medical Institute Floor 12 Room 12-20A (Lab) 1425 Madison Avenue New York, NY 10029 -  États-Unis
2 : Laboratoire de Biométrie et Biologie Evolutive  (LBBE)  -  Website
CNRS : UMR5558, Université Claude Bernard - Lyon I, INRIA
43 Bld du 11 Novembre 1918 69622 VILLEURBANNE CEDEX -  France
3 : Department of Microbiology & Immunology, Columbia University
701 W. 168 St., HHSC 1208 New York, NY 10032 -  États-Unis
4 : Institut de biologie et chimie des protéines  (IBCP)  -  Website
CNRS : UMR5086, Université Claude Bernard - Lyon I
7 Passage du Vercors 69367 LYON CEDEX 07 -  France
5 : Génomique virale et vaccination
Institut Pasteur de Paris
25, Rue du Docteur Roux 75724 PARIS CEDEX 15 -  France
* : Corresponding author

Lentiviral genomes present a strong nucleotide bias, with extremely high frequencies of the A nucleotide in HIV/SIV RNAs. Combining genomics, experimental and clinical data, we show a correlation between this bias and the pathogenicity of HIV-1. To study the effect of viral nucleotide composition on innate immunity stimulation, we developed an algorithm which uses the degeneracy of the genetic code to modulate the nucleotidic composition of genomic sequences without altering their regulatory elements or amino acid sequences. Then, we designed two artificial simian immunodeficiency viruses (SIV), whose genome sequences were optimized towards the macaque genome mean nucleotide composition. The first synthetic virus (SIVopt1) was optimized in gag and pol genomic regions and showed a dramatic decrease in replicativity. The second virus (SIVopt2) optimized only in pol, presented a similar replicative capacity to wild-type virus but its capacity to stimulate type-I interferon (IFN-I) in vitro was reduced. This synthetic virus with attenuated pathogenic potential open perspectives in HIV vaccine studies, particularly in regard to recent studies concerning codon-based immunity in HIV infections.


Online user: 1